Michelle Henley

Statistics

Publications

Citations

706

H-Index

Active since

2013

Affiliations

Novartis (United States)(Current)

Novartis (Switzerland)

Novartis (United Kingdom)

Tris Pharma (United States)

Respiratory Research Institute

Michelle Henley is an author at Novartis (United States) specializing in chronic obstructive pulmonary disease, pharmacotherapy, and pulmonary function testing.

Publications per year

2013–2016

Publications

Dual bronchodilation with QVA149<i>versus</i>single bronchodilator therapy: the SHINE study

Eric Bateman, Gary T. Ferguson, Neil Barnes et al. · European Respiratory Journal · 2013 · 381 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: The BRIGHT study

Kai-Michael Beeh, Stephanie Korn, Jutta Beier et al. · Respiratory Medicine · 2014 · 108 citations · Full text

Medicine, Pharmacotherapy, Exercise Physiology +16

A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study

Kenneth R. Chapman, Kai Michael Beeh, Jutta Beier et al. · BMC Pulmonary Medicine · 2014 · 84 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +16

Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study

Walter Vincken, Joseph Aumann, Hungta Chen et al. · International Journal of COPD · 2014 · 75 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study

Vivek Khanna, Gregory Feldman, Selwyn Spangenthal et al. · International Journal of COPD · 2016 · 24 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +16

1–5 of 7